Stay updated on SL-401 Combo in AML/MDS/BPDCN Clinical Trial
Sign up to get notified when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.

Latest updates to the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page
- Check5 days agoChange DetectedThe clinical trial record for SL-401 in combination with azacitidine, with or without venetoclax, is displayed instead of an error page. It includes study design and outcomes, participant eligibility, and contact details for three recruiting U.S. locations.SummaryDifference63%

- Check12 days agoChange DetectedThe site revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA notice about NIH’s terminology transition appears above the ClinicalTrials.gov 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the study page remains unavailable with a 403 error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the usual study details with an access-restricted notice. A Home button and site footer are displayed, indicating the study record is temporarily unavailable.SummaryDifference20%

- Check61 days agoChange DetectedThe page's contact information link label was standardized to 'Find contact information' and the revision tag was updated from v3.6.6 to v3.7.0.SummaryDifference0.1%

Stay in the know with updates to SL-401 Combo in AML/MDS/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.